GI
VIR icon

GAMMA Investing’s Vir Biotechnology VIR Stock Holding History

GAMMA Investing’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$65K Buy
5,815
+695
+14% +$6.95K ﹤0.01% 2189
2026
Q2 		$52.2K Buy
5,120
+152
+3% +$1.45K ﹤0.01% 2269
2026
Q1 		$44.5K Buy
4,968
+2,531
+104% +$20.2K ﹤0.01% 2253
2025
Q4 		$14.7K Buy
2,437
+797
+49% +$4.75K ﹤0.01% 2787
2025
Q3 		$9.36K Buy
1,640
+304
+23% +$1.55K ﹤0.01% 2910
2025
Q2 		$6.73K Sell
1,336
-5,775
-81% -$31K ﹤0.01% 2996
2025
Q1 		$46.1K Buy
7,111
+5,972
+524% +$53.1K ﹤0.01% 1848
2024
Q4 		$8.36K Sell
1,139
-292
-20% -$2.3K ﹤0.01% 2707
2024
Q3 		$10.7K Sell
1,431
-1,427
-50% -$12.4K ﹤0.01% 2425
2024
Q2 		$25.4K Buy
2,858
+150
+6% +$1.44K ﹤0.01% 1687
2024
Q1 		$27.4K Buy
2,708
+1,934
+250% +$19.7K 0.01% 1429
2023
Q4 		$7.28K Buy
+774
New +$7.07K ﹤0.01% 2063

Other funds holding VIR

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's VIR Position: Q3 2026 in Review

GAMMA Investing increased its Vir Biotechnology (VIR) stake by 14% in Q3 2026, buying an estimated $6.95K and bringing the position to 5,815 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #2189.

GAMMA Investing first reported a position in VIR in Q4 2023 and has held it in 12 quarters since. 6 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

  • GAMMA Investing held 5,815 shares of Vir Biotechnology worth $65K as of Q3 2026.
  • GAMMA Investing bought 695 Vir Biotechnology shares in Q3 2026, an estimated $6.95K.
  • Vir Biotechnology made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2189 holding.
  • GAMMA Investing first reported a position in Vir Biotechnology in Q4 2023 and has held it in 12 quarters since.
  • 6 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.